Straits Times Index
3,277.83 -15.30 (-0.46%) Nikkei
37,818.11 -641.97 (-1.67%) Hang Seng
17,318.10 +116.83 (+0.68%) FTSE 100
8,040.38 -4.43 (-0.06%) Bitcoin USD
64,399.95 -2,308.84 (-3.46%) CMC Crypto 200
1,388.67 -35.43 (-2.49%)
Nuwellis, Inc. (NUWE)
After hours:
| Previous close | 0.2964 |
| Open | 0.3000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.2500 - 0.3000 |
| 52-week range | 0.2400 - 5.7300 |
| Volume | |
| Avg. volume | 839,235 |
| Market cap | 2.064M |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -11.5200 |
| Earnings date | 07 May 2024 - 13 May 2024 |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | 5.25 |
GlobeNewswireNuwellis Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health
MINNEAPOLIS, April 09, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE) today announced that Detroit, Michigan-based health system, Henry Ford Health, has begun offering ultrafiltration therapy to heart failure patients suffering from fluid overload using the company’s Aquadex SmartFlow system as part of Nuwellis’ pivotal REVERSE-HF clinical study. “We are excited to study the impact of Aquadex SmartFlow therapy on our heart failure patients who are suffering from severe fluid overload,” s
Simply Wall St.Nuwellis Full Year 2023 Earnings: EPS Beats Expectations
Nuwellis ( NASDAQ:NUWE ) Full Year 2023 Results Key Financial Results Revenue: US$8.86m (up 3.8% from FY 2022). Net...
- GlobeNewswire
Late-Breaking Data Highlighting Benefits of Ultrafiltration Therapy Using the Aquadex System for Heart Failure Patients was Presented at the Technology and Heart Failure Therapeutics Conference
- Analysis demonstrates the statistically superior benefits of ultrafiltration therapy in heart failure events and heart failure hospitalizations compared to intravenous loop diuretics- Artificial intelligence and machine learning-based model show that lifestyle and clinical factors can be strong predictors of heart failure events MINNEAPOLIS, March 07, 2024 (GLOBE NEWSWIRE) -- Nuwellis, Inc. (Nasdaq: NUWE), a medical technology company focused on transforming the lives of people with fluid over
